Results from a Phase II trial have demonstrated the potential of GSK's first-in-class antitubercular agent to be a component of simpler treatment regimens for tuberculosis in the future.

GSK is returning to its long heritage in antibiotics with a potential first-in-class drug that has just shown promise in urinary tract infection; hopes are that it can reach annual sales of  $1bn.

GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.

Working with US FDA was key to developing clinical trials in the absence of regulatory precedents in recurrent vulvovaginal candidiasis, Scynexis VP tells the Pink Sheet; exposure profiles drove different trial designs for Scynexis’ Brexafemme and Mycovia’s just-launched Vivjoa.